{"id":"https://openalex.org/W2626411548","doi":"https://doi.org/10.1016/j.diabres.2017.06.018","title":"Use of SGLT2 inhibitors for diabetes and risk of infection: Analysis using general practice records from the NPS MedicineWise MedicineInsight program","display_name":"Use of SGLT2 inhibitors for diabetes and risk of infection: Analysis using general practice records from the NPS MedicineWise MedicineInsight program","alternate_titles":[],"publication_year":2017,"publication_date":"2017-06-16","ids":{"openalex":"https://openalex.org/W2626411548","doi":"https://doi.org/10.1016/j.diabres.2017.06.018","mag":"2626411548","pmid":"https://pubmed.ncbi.nlm.nih.gov/28646701"},"language":"en","primary_location":{"id":"doi:10.1016/j.diabres.2017.06.018","doi":"https://doi.org/10.1016/j.diabres.2017.06.018","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.diabres.2017.06.018","pdf_url":null,"source":{"id":"https://openalex.org/S171311646","display_name":"Diabetes Research and Clinical Practice","issn_l":"0168-8227","issn":["0168-8227","1872-8227"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes Research and Clinical Practice","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2626411548"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.1016/j.diabres.2017.06.018","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5014227123","display_name":"Svetla Gadzhanova","orcid":"https://orcid.org/0000-0002-7493-7387","observed_orcids":["https://orcid.org/0000-0002-7493-7387"]},"institutions":[{"id":"https://openalex.org/I170239107","display_name":"University of South Australia","ror":"https://ror.org/01p93h210","country_code":"AU","type":"education","lineage":["https://openalex.org/I170239107","https://openalex.org/I4405259444"]}],"countries":["AU"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Svetla Gadzhanova","raw_affiliation_strings":["Quality Use of Medicines and Pharmacy Research Centre, University of South Australia, Australia. Electronic address: Svetla.Gadzhanova@unisa.edu.au","Quality Use of Medicines and Pharmacy Research Centre, University of South Australia, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Quality Use of Medicines and Pharmacy Research Centre, University of South Australia, Australia. Electronic address: Svetla.Gadzhanova@unisa.edu.au","institution_ids":["https://openalex.org/I170239107"]},{"raw_affiliation_string":"Quality Use of Medicines and Pharmacy Research Centre, University of South Australia, Australia","institution_ids":["https://openalex.org/I170239107"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058616004","display_name":"Nicole L. Pratt","orcid":"https://orcid.org/0000-0001-8730-8910","observed_orcids":["https://orcid.org/0000-0001-8730-8910"]},"institutions":[{"id":"https://openalex.org/I170239107","display_name":"University of South Australia","ror":"https://ror.org/01p93h210","country_code":"AU","type":"education","lineage":["https://openalex.org/I170239107","https://openalex.org/I4405259444"]}],"countries":["AU"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Nicole Pratt","raw_affiliation_strings":["Quality Use of Medicines and Pharmacy Research Centre, University of South Australia, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Quality Use of Medicines and Pharmacy Research Centre, University of South Australia, Australia","institution_ids":["https://openalex.org/I170239107"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5051519595","display_name":"Elizabeth Ellen Roughead","orcid":"https://orcid.org/0000-0002-6811-8991","observed_orcids":["https://orcid.org/0000-0002-6811-8991"]},"institutions":[{"id":"https://openalex.org/I170239107","display_name":"University of South Australia","ror":"https://ror.org/01p93h210","country_code":"AU","type":"education","lineage":["https://openalex.org/I170239107","https://openalex.org/I4405259444"]}],"countries":["AU"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Elizabet Roughead","raw_affiliation_strings":["Quality Use of Medicines and Pharmacy Research Centre, University of South Australia, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Quality Use of Medicines and Pharmacy Research Centre, University of South Australia, Australia","institution_ids":["https://openalex.org/I170239107"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5014227123"],"corresponding_institution_ids":["https://openalex.org/I170239107"],"apc_list":{"value":4410,"currency":"USD","value_usd":4410},"apc_paid":{"value":4410,"currency":"USD","value_usd":4410},"fwci":4.8961,"has_fulltext":false,"cited_by_count":67,"citation_normalized_percentile":{"value":0.9626301,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":87,"max":99},"biblio":{"volume":"130","issue":null,"first_page":"180","last_page":"185"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9926999807357788,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9926999807357788,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.0031999999191612005,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/sglt2-inhibitors","display_name":"SGLT2 inhibitors","score":1.0},{"id":"https://openalex.org/keywords/dapagliflozin","display_name":"dapagliflozin","score":0.9860000014305115},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9710000157356262},{"id":"https://openalex.org/keywords/genital-tract-infection","display_name":"genital tract infection","score":0.6439999938011169},{"id":"https://openalex.org/keywords/urinary-tract-infection","display_name":"urinary tract infection","score":0.9079999923706055},{"id":"https://openalex.org/keywords/dpp-4-inhibitors","display_name":"DPP-4 inhibitors","score":0.9789999723434448},{"id":"https://openalex.org/keywords/risk-management-plan","display_name":"risk management plan","score":0.8130000233650208},{"id":"https://openalex.org/keywords/renal-function-monitoring","display_name":"renal function monitoring","score":0.6309999823570251},{"id":"https://openalex.org/keywords/metformin","display_name":"metformin","score":0.828000009059906},{"id":"https://openalex.org/keywords/sulfonylureas","display_name":"sulfonylureas","score":0.9539999961853027},{"id":"https://openalex.org/keywords/general-practice-records","display_name":"general practice records","score":0.5070000290870667}],"concepts":[{"id":"https://openalex.org/C2777422806","wikidata":"https://www.wikidata.org/wiki/Q409898","display_name":"Dapagliflozin","level":4,"score":0.9734439849853516},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9480586051940918},{"id":"https://openalex.org/C2780323712","wikidata":"https://www.wikidata.org/wiki/Q19484","display_name":"Metformin","level":3,"score":0.7774584293365479},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.652739405632019},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.5969880819320679},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.5948047637939453},{"id":"https://openalex.org/C167135981","wikidata":"https://www.wikidata.org/wiki/Q2146302","display_name":"Retrospective cohort study","level":2,"score":0.5283005237579346},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.512117862701416},{"id":"https://openalex.org/C201903717","wikidata":"https://www.wikidata.org/wiki/Q1778788","display_name":"Cohort study","level":2,"score":0.4965584874153137},{"id":"https://openalex.org/C77411442","wikidata":"https://www.wikidata.org/wiki/Q181100","display_name":"Urinary system","level":2,"score":0.4349309504032135},{"id":"https://openalex.org/C2778854520","wikidata":"https://www.wikidata.org/wiki/Q418776","display_name":"Sulfonylurea","level":3,"score":0.4250923991203308},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.18178972601890564}],"mesh":[{"descriptor_ui":"D000077203","descriptor_name":"Sodium-Glucose Transporter 2 Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D001315","descriptor_name":"Australia","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D001559","descriptor_name":"Benzhydryl Compounds","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D001559","descriptor_name":"Benzhydryl Compounds","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000382","qualifier_name":"microbiology","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005960","descriptor_name":"Glucosides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D005960","descriptor_name":"Glucosides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D008137","descriptor_name":"Longitudinal Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014552","descriptor_name":"Urinary Tract Infections","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D014552","descriptor_name":"Urinary Tract Infections","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D014552","descriptor_name":"Urinary Tract Infections","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D014552","descriptor_name":"Urinary Tract Infections","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D015331","descriptor_name":"Cohort Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051297","descriptor_name":"Sodium-Glucose Transporter 2","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D054873","descriptor_name":"Dipeptidyl-Peptidase IV Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D054873","descriptor_name":"Dipeptidyl-Peptidase IV Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D057286","descriptor_name":"Electronic Health Records","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058006","descriptor_name":"General Practice","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1016/j.diabres.2017.06.018","doi":"https://doi.org/10.1016/j.diabres.2017.06.018","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.diabres.2017.06.018","pdf_url":null,"source":{"id":"https://openalex.org/S171311646","display_name":"Diabetes Research and Clinical Practice","issn_l":"0168-8227","issn":["0168-8227","1872-8227"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes Research and Clinical Practice","raw_type":"journal-article"},{"id":"pmid:28646701","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/28646701","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes research and clinical practice","raw_type":"Journal Article"},{"id":"pmh:oai:urm_publish:9916141711301831","doi":null,"is_oa":true,"landing_page_url":"https://find.library.unisa.edu.au/discovery/fulldisplay/alma9916141711301831/61USOUTHAUS_INST:ROR","pdf_url":null,"source":{"id":"https://openalex.org/S4306402528","display_name":"UniSA Research Outputs Repository (University of South Australia)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I170239107","host_organization_name":"University of South Australia","host_organization_lineage":["https://openalex.org/I170239107"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"text"},{"id":"pmh:oai:digital.library.adelaide.edu.au:11541.2/127542","doi":null,"is_oa":true,"landing_page_url":"https://hdl.handle.net/11541.2/127542","pdf_url":null,"source":{"id":"https://openalex.org/S4306401835","display_name":"Adelaide Research & Scholarship (AR&S) (University of Adelaide)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I5681781","host_organization_name":"The University of Adelaide","host_organization_lineage":["https://openalex.org/I5681781"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"https://doi.org/10.1016/j.diabres.2017.06.018","raw_type":"Journal article"}],"best_oa_location":{"id":"doi:10.1016/j.diabres.2017.06.018","doi":"https://doi.org/10.1016/j.diabres.2017.06.018","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.diabres.2017.06.018","pdf_url":null,"source":{"id":"https://openalex.org/S171311646","display_name":"Diabetes Research and Clinical Practice","issn_l":"0168-8227","issn":["0168-8227","1872-8227"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes Research and Clinical Practice","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":7,"referenced_works":["https://openalex.org/W2072040765","https://openalex.org/W2114031829","https://openalex.org/W2144742353","https://openalex.org/W2153405690","https://openalex.org/W2162427196","https://openalex.org/W2167793764","https://openalex.org/W3185873161"],"related_works":["https://openalex.org/W7214728059","https://openalex.org/W2790579026","https://openalex.org/W2619772777","https://openalex.org/W4206018554","https://openalex.org/W2954115740","https://openalex.org/W2551376414","https://openalex.org/W4224327037","https://openalex.org/W7163680278","https://openalex.org/W4206566081","https://openalex.org/W4409094717"],"abstract_inverted_index":{"AIMS:":[0],"To":[1],"explore":[2],"the":[3,99,111,115,137,149,157,168,183,187],"feasibility":[4],"of":[5,69,81,154,207,220],"MedicineInsight":[6],"data":[7],"to":[8,45,51,167,199,223],"support":[9],"risk":[10,206,219],"management":[11],"plan":[12],"evaluation,":[13],"focusing":[14],"on":[15,105],"sodium":[16],"glucose":[17],"co-transporter":[18],"2":[19,24,127],"(SGLT2)":[20],"inhibitors":[21,213],"for":[22,65,79,123,145],"type":[23,126],"diabetes.":[25],"METHODS:":[26],"A":[27],"retrospective":[28],"study":[29],"using":[30],"de-identified":[31],"electronic":[32],"general":[33],"practitioner":[34],"records.":[35],"Patients":[36],"who":[37,53],"initiated":[38,54,104],"SGLT2":[39,82,100,116,160,184,212],"inhibitor":[40],"between":[41],"1":[42,46],"Jan":[43],"2012":[44],"Sep":[47],"2015":[48],"were":[49,63,91,95,179],"compared":[50,166,222],"patients":[52],"dipeptidyl":[55],"peptidase":[56],"4":[57],"(DPP-4)":[58],"inhibitors.":[59],"The":[60,77,152],"two":[61],"cohorts":[62],"followed-up":[64],"six":[66],"months.":[67],"Risk":[68],"urinary-tract":[70],"(UT)":[71],"and":[72,88,107],"genital":[73,208],"infections":[74],"was":[75,143,162],"evaluated.":[76],"indication":[78,122],"use":[80,124],"inhibitors,":[83],"recommended":[84,89],"prior":[85,138],"diabetes":[86],"therapies":[87],"monitoring":[90,142],"investigates.":[92],"RESULTS:":[93],"There":[94],"1977":[96],"people":[97,109],"in":[98,110,136,148,156,182,186],"cohort":[101,170,189],"(with":[102],"93%":[103],"dapagliflozin)":[106,215],"1964":[108],"DPP-4":[112,169,188,224],"cohort.":[113],"Of":[114],"initiators,":[117],"54%":[118],"had":[119,130],"a":[120,134,204],"documented":[121,144],"as":[125],"diabetes;":[128],"86%":[129],"used":[131],"metformin":[132],"and/or":[133],"sulfonylurea":[135],"12months.":[139],"Renal":[140],"function":[141],"only":[146],"25%":[147],"6months":[150,158],"initiation.":[151],"frequency":[153],"UTI":[155],"post":[159],"initiation":[161],"not":[163],"significantly":[164],"increased":[165,218],"(3.6%vs":[171],"4.9%;":[172],"aHR=0.90,":[173],"95%":[174,194],"CI":[175,195],"0.66-1.24).":[176],"Genital":[177],"infection":[178,209],"more":[180],"frequent":[181],"than":[185],"(2.9%":[190],"vs":[191],"0.9%,":[192],"aHR=3.50,":[193],"1.95-5.89).":[196],"CONCLUSIONS:":[197],"Similar":[198],"existing":[200],"evidence,":[201],"we":[202],"found":[203],"higher":[205],"associated":[210],"with":[211],"(primarily":[214],"but":[216],"no":[217],"UTIs":[221],"use.":[225]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2626411548","counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":7},{"year":2024,"cited_by_count":5},{"year":2023,"cited_by_count":6},{"year":2022,"cited_by_count":9},{"year":2021,"cited_by_count":8},{"year":2020,"cited_by_count":10},{"year":2019,"cited_by_count":8},{"year":2018,"cited_by_count":9},{"year":2017,"cited_by_count":1}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2017-06-23T00:00:00"}
